High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector
Open Access
- 1 November 2007
- journal article
- Published by Microbiology Society in Journal of General Virology
- Vol. 88 (11) , 2915-2924
- https://doi.org/10.1099/vir.0.83119-0
Abstract
Replication-incompetent adenovirus type 35 (rAd35) represents a potent vaccine carrier that elicits strong, antigen-specific T- and B-cell responses in diverse preclinical models. Moreover, Ad35 is rare in human populations, resulting in the absence of neutralizing antibodies against this carrier, in contrast to the commonly used rAd5. Therefore, rAd35 is being investigated as a vaccine carrier for a number of diseases for which an effective vaccine is needed, including malaria, AIDS and tuberculosis. However, it can be perceived that effective immunization will require insertion of multiple antigens into adenoviral vectors. We therefore wanted to create rAd35 vectors carrying double expression cassettes, to expand within one vector the number of insertion sites for foreign DNA encoding antigenic proteins. We show that it is possible to generate rAd35 vectors carrying two cytomegalovirus promoter-driven expression cassettes, provided that the polyadenylation signals in each expression cassette are not identical. We demonstrate excellent rAd35 vector stability and show that expression of a transgene is not influenced by the presence of a second expression cassette. Moreover, by using two model vaccine antigens, i.e. the human immunodeficiency virus-derived Env-gp120 protein and the Plasmodium falciparum-derived circumsporozoite protein, we demonstrate that potent T- and B-cell responses are induced to both antigens expressed from a single vector. Such rAd35 vectors thus expand the utility of rAd35 vaccine carriers for the development of vaccines against, for example, malaria, AIDS and tuberculosis.Keywords
This publication has 22 references indexed in Scilit:
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus VectorThe Journal of Infectious Diseases, 2006
- Alteration of epitope recognition pattern in Ag85B and ESAT‐6 has a profound influence on vaccine‐induced protection against Mycobacterium tuberculosisEuropean Journal of Immunology, 2006
- Circumventing Recombination Events Encountered with Production of a Clinical-Grade Adenoviral Vector with a Double-Expression CassetteMolecular Pharmacology, 2006
- Binary AdEasy vector systems designed for Tet-ON or Tet-OFF regulated control of transgene expressionVirus Research, 2006
- Multigene expression from a replicating adenovirus using native viral promotersMolecular Therapy, 2003
- New tools for the generation of E1- and/or E3-substituted adenoviral vectorsGene Therapy, 2000
- New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent AdenovirusesHuman Gene Therapy, 1998
- Construction of a Double Recombinant Adenovirus Vector Expressing a Heterodimeric Cytokine:In VitroandIn VivoProduction of Biologically Active Interleukin-12Human Gene Therapy, 1996
- Subgroup B Adenovirus Type 35 Early Region 3 mRNAs Differ from Those of the Subgroup C AdenovirusesVirology, 1996
- An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.Proceedings of the National Academy of Sciences, 1994